



**GlaxoSmithKline  
Supplier Diversity  
5 Moore Drive  
PO Box 13398  
Durham, NC 27709-3398**  
  
Tel. 919.315.3781  
Fax: 336.369.8974  
www.gsk.com

VIA ELECTRONIC MAIL ([AGO.highcostprescriptiondrugs@vermont.gov](mailto:AGO.highcostprescriptiondrugs@vermont.gov))

April 26, 2021

Office of The Attorney General  
State of Vermont  
Attn: TJ Donovan, Attorney General  
109 State Street  
Montpelier, VT 05609

RE: Notice of New Prescription Drug Pursuant to 18 V.S.A §4637(b)

Dear Mr. Donovan:

GlaxoSmithKline ("GSK") is issuing this notice pursuant to 18 V.S.A §4637(b) to inform you that on April 23, 2021 GSK introduced a new prescription drug to market (in the U.S. and Vermont) at a wholesale acquisition price above the threshold set for a specialty drug under the Medicare Part D program.

The new drug, listed below with its respective NDC, is:

- (1) JEMPERLI, JEMPERLI INJ 500MG/10ML (NDC: 00173089803)

Please let me know if you have any questions about this notice or the products referenced herein.

Regards,

**Jennifer Smith**  
**Pricing Operations Manager**  
Payer Marketing  
US

Email [Jennifer.3.smith@gsk.com](mailto:Jennifer.3.smith@gsk.com)